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OBJECTIVES: Approximately 250,000 patients per year are admitted to hospitals in 
the United Kingdom (UK) with skin and soft tissue (SSTI) infections, accounting for 
~1.6% of hospital admissions. Staphylococcus aureus accounts for > 50% of SSTIs; 
methicillin-resistant Staphylococcus aureus(MRSA) infections represent approxi-
mately 13.7% of those. Treatment of SSTIs is costly and often involves intravenous 
(IV) antibiotic therapy, hospitalization of ≥ 10 days and may involve both inpatient 
stay and multi-day follow-up outpatient antibiotic parenteral therapy (OPAT). 
Hospitals and healthcare systems may reduce the economic burden of hospitalized 
patients through the use of OPAT and/or early hospital discharge. Oritavancin is a 
single, once only 1200 mg IV dose for the treatment of SSTIs caused by gram posi-
tive bacteria, including MRSA. The aim of this analysis was to quantify the annual 
economic impact to a UK hospital of using oritavancin in select moderate-to-severe 
SSTI patients. METHODS: A decision tree based on current clinical practice was 
constructed to estimate the economic value of using oritavancin. Current and future 
utilization of antibiotics were informed by published literature and clinical expert 
opinion. Clinical data were derived from the literature and oritavancin’s pivotal 
phase III studies. Drug costs were derived from the British National Formulary. 
Other included costs were based on the UK 2014 NHS reference costs. RESULTS: 
For a UK hospital treating 100 SSTI patients per year eligible for IV antibiotics, using 
oritavancin conservatively (3.6% of patients) would decrease total annual cost by 
£2,922.52. Increased pharmaceutical costs (£6,111.21) were offset by reductions in 
drug administration costs (-£5,531.13) and hospitalization/OPAT costs (-£3,379.48). 
Inpatient and outpatient days of treatment were reduced by 8.2 and 16.4 days, 
respectively. CONCLUSIONS: Using oritavancin conservatively in moderate-to-
severe SSTI patients is estimated to reduce costs by £29.23/patient by shifting 
patient care to the outpatient setting, allowing for early discharge, and reducing 
hospitalization and drug administration costs.
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OBJECTIVES: Clostridium difficile infection (CDI) is a debilitating illness. In two 
phase III trials fidaxomicin produced comparable initial cure rates, significantly 
lower recurrence rates (p< 0.005) and significantly higher sustained cure rates 
(p= 0.001) versus vancomycin. This cost-effectiveness and budget impact model 
analysed the costs and outcomes of vancomycin and fidaxomicin for treatment 
of CDI in Germany. METHODS: The model was a Markov cohort simulation, with 
10-day cycle length. The analysis timescale was either 40 days (hospital perspec-
tive) or 1 year (payer perspective). Clinical inputs included : 30-day CDI-attributable 
mortality, probability of clinical cure and 30-day probability of recurrence after end 
of treatment. The first-line treatment is either Dificlir (€ 1300) or vancomycin (€ 61). 
Second line treatment is user defined, and in the base case is vancomycin. Third line 
treatment is a rescue treatment (€ 1500), assumed to have 100% cure rate. The model 
is populated with cost data for Germany. Drug costs are based on list prices, and the 
costs of hospitalisation are DRG tariff rates; Cost per day of CDI treated on a general 
ward (€ 348). A deterministic sensitivity analysis was carried out to test the robust-
ness of the model outcomes. The cost-effectiveness of six CDI patient subgroups 
was also analysed based on the two fidaxomicin clinical trials’ results. RESULTS: 
The outcomes of the model for All Patient group: incremental cost per QALY gained 
€ 40,807, cost per recurrence avoided € 2,068, and cost per bed-day saved € 110. For 
the All Patient group fidaxomicin reduced the number of recurrences by 49%. Fewer 
recurrences led to a reduction in attributable deaths, a gain in life years; an improve-
ment in quality of life; and a reduction in the number of bed-days. CONCLUSIONS: 
First-line fidaxomicin is likely to be a cost-effective treatment option, compared to 
vancomycin at a willingness to pay threshold of € 50,000 per QALY gained.
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OBJECTIVES: This research aims to assess the economic impact and cost-utility of 
replacing trivalent inactivated influenza vaccines (IIV3) with the newer influenza 
vaccines – trivalent high dose (HD) or quadrivalent (IIV4) influenza vaccine in adults 
aged 65 and older under Ontario’s Universal Influenza Immunization Program (UIIP) 
from healthcare and societal perspectives. METHODS: An analytical decision model 
was developed for the elderly (age 65-74, 75-84, and 85 and above) at two levels of 
health risks (high and low) with influenza-related health outcomes from Ontario or 
Canada. Ontario’s demographic data and labor costs were extracted from Statistics 
Canada. Vaccine efficacies were based on post-marketing clinical study for HD and 
estimated from published literatures for IIV4. Antiviral treatment and over-the-
counter medication costs were considered. Deterministic (DSA) and probabilistic 
sensitivity analyses (PSA) were conducted. Additional analysis was performed for 
long-term impact of influenza infections. RESULTS: Comparing to IIV3 under UIIP, 
IIV3 HD has a net societal budget impact of C$346,809 including premature deaths in 
a single influenza season. The incremental cost-effectiveness ratio (ICER) is C$3,763 
per QALY gained from healthcare perspective and C$190 per QALY gained from 
Canada, 3University of Calgary, Calgary, AB, Canada
OBJECTIVES: Paediatric advisory guidelines recommend prophylaxis against 
respiratory syncytial virus (RSV) for infants with hemodynamically significant 
congenital heart disease (HSCHD). However, current recommendations have 
cast doubt as to whether prophylaxis is beneficial after 1year of age. The objec-
tive of this study is to determine whether there are differences in RSV-related 
hospitalizations (RSVH) in HSCHD infants receiving palivizumab during the first 
versus second season in the Canadian Registry of palivizumab (CARESS) data-
base. METHODS: CARESS is a prospective registry of infants who have received 
≥ 1 dose of palivizumab at one of 32 sites across Canada during the 2005-2014 
RSV seasons. Demographic data were collected at enrollment and respiratory-
illness-related hospitalization events were recorded monthly. Only infants aged 
< 24 months with HSCHD were included in the analysis. RESULTS: 707 (35.1%) of 
2013 infants were prophylaxed during the second season (average age in months: 
4.7 [first season] vs 14.7 [second season]). There were no significant differences 
between first- and second-season infants in terms of baseline demographics. 
However, infants aged > 1year had a more complicated neonatal course, with sig-
nificantly longer neonatal length of stay (46.7 versus 25.6 days). 26 infants in the 
first year (RSVH rate: 2.26%) and 11 infants in the second year of prophylaxis (RSVH 
rate: 2.09%) were hospitalized. A Cox regression found that there were neither 
significant differences in hazards between infants in their first or second year of 
prophylaxis in terms of time to first RSVH nor relevant predictors of the neonatal 
course. CONCLUSIONS: Infants enrolled in the CARESS database in the second 
RSV season had a similar hazard of RSVH as those in the first year of life. These 
findings suggest that infants aged > 1 year are equally at risk for RSVH and benefit 
from palivizumab prophylaxis.
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OBJECTIVES: Pertussis (whooping cough) is an acute, highly contagious infec-
tious disease, causing uncontrollable and severe coughing. Pertussis outbreaks 
are increasingly common, but little is available on their determinants. Through a 
systematic literature review, this study aims at describing key drivers of pertussis 
outbreaks, and at listing reported recommendations. METHODS: A systematic 
review of literature on pertussis outbreaks was conducted, including references 
published between 2011 and 2014, using Medline, Embase, the Cochrane library 
and relevant websites as potential sources. All population-based studies report-
ing information about epidemiology, burden or costs of pertussis outbreaks were 
included, without geographical restriction. RESULTS: Thirty-eight observational 
studies from 14 countries were included. Three different kinds of key drivers 
were identified by authors. Disease-related drivers included delays occurring in 
diagnosis and isolation of cases, natural cyclic variations and possible pathogen-
speciﬁc changes. Healthcare management-related drivers included differences 
in physician awareness and/or underuse of laboratory diagnosis method. Finally 
booster-related drivers included low vaccination coverage and waning vaccine-
mediated immunity. Most studies attempted to provide recommendations. The 
need for vaccination campaigns was clearly stated in several studies, such as 
new vaccination strategies (vaccination of adults, maternal immunisation, ear-
lier booster dose, cocooning strategy, etc.) or more generally availability of vac-
cines providing long-lasting immunity. Systematic laboratory confirmations 
and systematic reporting were also suggested to reduce the burden of pertus-
sis. CONCLUSIONS: These results highlight the need to improve monitoring 
the epidemiology of pertussis, areas for improvement for pertussis healthcare 
management and the need to have boosters with optimal timing within the 
routine immunisation schedule. Additional research is to be carried out to sup-
port health authorities in the choice of the most adapted national vaccination 
programme.
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OBJECTIVES: HIV and AIDS is a major cause of premature death and impose a 
large socioeconomic burden in Kenya. Antiretroviral treatment (ART) is one of 
the interventions being implemented to mitigate these impacts. Studies on the 
survival rate and the socioeconomic factors explaining survival of patients on 
treatment follow up are very rare in Kenya. The objective of this research was to 
estimate the survival rate and factors associated with survival of the HIV positive 
patients on ART and those not on ART. METHODS: Baseline characteristic of adults 
on ART and those not on ART with CD4 counts 250 and below at enrolment were 
collected from the patient charts between 2003 to 2010, from Mbagathi District 
Hospital (Mbagathi) (n= 300) and Moi Teaching and Referral Hospital (Moi) in Kenya 
(n= 400). Kaplan Meier and life table analysis were used and survival durations 
measured in 3 monthly intervals. RESULTS: The survival rate declined over time. 
Approximately 3% of the patients died within the first three months of treatment 
debut and 57% were still alive at the time of this study (after 78 months of fol-
low up). 25% of the patients in Mbagathi died by the 11th cycle (33 months) (95% 
CI[7-15]) where as 25% of patients in Moi died by the 16th cycle (48 months) (95% 
CI[14-19]). In addition, after the initial 30 months of treatment follow up 77%, (95% 
CI[71.7-81.3%]) of patient enrolled in Mbagathi and 91.9%, (95% CI[88.5-94.3%]) 
enrolled in Moi were still alive, showing better survival rate of patients in Moi. 
The patients on ARVs were likely to survive longer than those not on ART, the 
female and married patients were also likely to survive longer than their male 
and unmarried counterparts. CONCLUSIONS: The study findings shows that ART 
increases the survival rates, being female and married are also associated with 
increased survival rates.
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the comparable estimates would be C$11.65/person (HC) and C$0.84/person (FC). 
ICER of HD vs IIV3 was C$190/QALY with HC approach and C$3,106/QALY with FC. 
In comparison, the difference of ICERs of IIV4 vs IIV3 was small - $16,232/QALY (HC) 
and C$19,028/QALY (FC). Exclusion of productivity costs of mortality had minimal 
impact with similar ICERs to FC method. CONCLUSIONS: The differences in ICERs of 
IIV4 vs IIV3 with HC method, FC method or no productivity costs of mortality were 
significantly narrower than those of HD vs IIV3. Relative vaccine efficacy against 
influenza-related deaths to IIV3 was a key driver of productivity costs; therefore, 
choice of methods could be crucial with massively different results. Those conclu-
sions were robust to alternative friction periods and elastic factors.
PIn39
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OBJECTIVES: Colombia is an endemic country for malaria. Burden of disease and 
costs estimations are scarce. The aim of this analysis is to estimate the burden 
of disease and the diagnosis and care costs of malaria, from the surveillance 
data. METHODS: A malaria transmission model was built from an age-dependent 
Markov process, to simulate the morbidity and mortality of the malaria infection 
in the Colombian population from the national surveillance system and other 
literature. The model included a birth cohort followed up to their life expectancy. 
We estimated the number of malaria, malaria complicates and death cases in the 
cohort during the life span. From the official malaria diagnosis and treatment 
guidelines we captured the frequency of use for all cost items and calculated 
the cost per patient from the tariff manual and international prices. Cost esti-
mation was carried out from the third payer perspective. We estimated the dis-
ability adjusted life years (DALYs) and diagnosis and care costs for each malaria 
case and entire population during 2012 splitting by different Plasmodium specie. 
All costs were reported in 2012 American dollars (exchange rate of US$ 1768.23.
per COP). RESULTS: During 2012 we estimated 65.448 cases and 32 deaths due 
to malaria. The 71.7% of cases were due to P. vivax and 27.0% by P. falciparum. 
Complications were presented in 1% of all cases. All malaria cases sum a burden 
of disease of 1902 DALYs (mainly due to year of life lost-YLL, 1878). Total estimated 
cost was US$936.253, 5% of them due to complicated malaria. CONCLUSIONS: 
Burden and costs of disease due to malaria in Colombia are relevant in spite of 
availability of effective preventive measurements. Cost-effectiveness of different 
public health interventions should be evaluate for the decision making process 
and this model will be a valuable input for that task.
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OBJECTIVES: Data on costs of surgical site infections (SSIs) following ambulatory 
surgery are sparse, despite a shift towards outpatient procedures. We determined 
the impact of serious and non-serious SSIs on healthcare costs following common 
ambulatory surgical procedures throughout the cost distribution. METHODS: We 
conducted a retrospective cohort study of persons < 65 years coded for cholecys-
tectomy, breast-conserving surgery (BSC), anterior cruciate ligament reconstruction 
(ACL), or hernia repair from 12/31/2004–12/31/2010 using commercial insurer claims 
data. SSIs within 90 days after surgery were identified by ICD-9-CM diagnosis codes. 
Infections during inpatient hospitalization or resulting in surgical treatment were 
considered serious. Quantile regression controlling for underlying illness, operative 
variables, demographics, and surgical facility type was used to examine the impact 
of serious and non-serious SSIs on 180-day healthcare costs. RESULTS: The inci-
dence of serious/non-serious SSIs (# procedures) were 0.8%/0.2% after ACL (21,062), 
0.5%/0.3% after cholecystectomy (57,750), 0.6%/0.5% after hernia repair (60,681), and 
0.8%/0.8% after BCS (42,489). Serious SSIs were associated with significantly higher 
costs than non-serious SSIs for ACL, cholecystectomy, and hernia repair at all points 
examined in the cost distribution. For BCS, serious SSIs were associated with sig-
nificantly higher costs at the upper end (> = 80th percentile) of the cost distribution. 
The ratio of adjusted total costs for individuals with serious SSI vs. no SSI increased 
for both cholecystectomy and hernia repair as the total cost increased (3.2 for chol-
ecystectomy with serious SSI/no SSI at the 70th percentile of costs, up to 4.9 at the 
95thpercentile). CONCLUSIONS: SSIs, particularly serious infections resulting in 
hospitalization or surgical treatment, were associated with significantly increased 
healthcare costs after 4 common surgical procedures performed in inpatient and 
ambulatory settings. Quantile regression illustrated the impact of serious SSIs on 
healthcare costs across the distribution of costs, especially at the upper end of the 
cost distribution.
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OBJECTIVES: Antibiotic resistance (ABR) poses a threat to public health in the United 
States (US). The Centers for Disease Control and Prevention has identified three 
ABR urgent threats (defined as potential clinical and economic impact, transmis-
sibility, available treatment, barriers to prevention): Clostridium difficile (C. diff), 
carbapenem-resistent Enterobacteriaceae (CRE), and Neisseria gonorrhoeae (N. gon-
orrhoeae). Limited data exist which document ABR-related burden in the context 
of inpatient care. This study examines length of stay (LOS) and costs associated 
with ABR urgent threat-related hospitalizations in the US. METHODS: Using the 
2001-2012 Healthcare Cost and Utilization Project’s Nationwide Inpatient Sample 
databases, nationally-representative surveys of US hospitalizations, we identified 
hospitalizations with a diagnosis code indicating an urgent ABR threat. LOS and 
societal perspective. Replacing IIV3 with IIV4 would result a net societal budget 
impact of over C$3 million. The ICER of IIV4 vs IIV3 is C$20,733 per QALY gained 
from healthcare perspective and societally C$16,232 per QALY gained. At $50,000 
per QALY gained threshold, 100% and 93.8% of PSA simulations were cost-effective 
for HD and IIV4, respectively, from healthcare perspective, and 95.3% for IIV4 from 
societal perspective. HD becomes a dominant alternative when long-term care costs 
are considered. CONCLUSIONS: Both HD and IIV4 are expected to reduce influenza-
associated morbidity and mortality, and are cost-effective in the studied population 
comparing to IIV3; however, IIV4 is extended dominated by HD. Those conclusions 
were proven to be robust in sensitivity analyses.
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OBJECTIVES: Access to effective, low cost antiretrovirals (ARVs) is a public health 
imperative. This study compared ARV approvals and prices in Saudi Arabia (SA) 
and the United States (US) in 2014. METHODS: US Food and Drug Administration 
(FDA) ARV drug approvals data were collected from the FDA website. Likewise, 
ARV drug approvals and prices in SA were collected from the Saudi Food and Drug 
Administration (SFDA) website. ARV drug prices data were also collected from the 
World Health Organization (WHO) website. Descriptive analysis and paired t-test 
were performed. Statistical significance was set up at 0.05% RESULTS: In 2014, there 
were 27 ARVs and 9 fixed-dose combinations of ARVs approved by the FDA. The WHO 
listed 22 ARV single active ingredients and 16 combinations. Overall, 29.6% of the 
single active ingredients and 33.3% of the combinations approved by the FDA were 
marketed in SA. The FDA approved generic ARVs for 18.5% of the single active ingre-
dients and for 22.2% of the combinations. The WHO listed generic ARVs for 31.8% of 
the single active ingredients and 100% of the combination drugs. No generic ARV 
drugs were approved by the SFDA. Price data were available for 13 drugs. ARV drug 
prices in SA were in median 21.14 times higher than the ARV drug prices listed by the 
WHO (range 2.2 - 99.8 times) (p< 0.0001). CONCLUSIONS: Less than one third of the 
ARV drugs approved by the US FDA were marketed in SA in 2014. Prices in SA were 
significantly higher than prices listed by the WHO. Lack of SFDA approved generic 
ARVs may explain the price difference. Approvals of low cost generic ARVs remains 
a public health priority in SA to improve quality of life of HIV patients in the country.
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OBJECTIVES: To evaluate the cost of influenza vaccination, the sources of financing, 
and drug cost compared to the cost of vaccination in Ukraine. METHODS: We used 
the statistic data of the MoH of Ukraine, data about the rate of influenza vaccina-
tion. Comparative analysis of retrospective data on consumption of drugs and the 
cost of influenza vaccine. RESULTS: Vaccination against influenza and other acute 
respiratory infections (ARI) are not included in the list of obligatory vaccinations and 
not funded by the state, partially it funded from local budgets in Ukraine. During 
2009-2010 flu had pandemic status, but the number of vaccinated people was mini-
mal. It has been vaccinated 239104 people, among them the expense of businesses 
- 94546 (39.5%), local budgets - 106498 (44.5%) and patient funds - 38060 (15.9%). Only 
2.18% people over 60 years were vaccinated, but this category represents 15.9% of 
the total population. We conducted that average cost of flu vaccination was 101,0 
UAH (1 USD = 16,5 UAH). The average cost of ambulatory treatment per patient 
was 241,1 UAH, it was 2,4 times more than the vaccination cost Analysis of sales 
of drugs used for treatment of flu and ARI showed: NSAIDS were spent 118,8 mln. 
UAH., Expectorants - 275,3 mln., Antibiotics – 218,1 mln., but the cost of vaccines 
were 23,2 mln. UAH. The comparison showed that the cost of drugs for the treatment 
of influenza and ARI were at 26.4 times more than vaccines. CONCLUSIONS: We 
evaluated the high rate of incidence of influenza, low rate of influenza vaccination 
in 2009, a low percentage of vaccination of health-risk groups (for example, 60 +), the 
high cost on drugs to treat the flu and ARI. It confirmed the economic expediency 
of using influenza vaccine in Ukraine.
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OBJECTIVES: Although employment rate is lower in the elderly population, different 
methods valuing productivity loss can yield contrasting incremental cost-effective-
ness ratios (ICER). This research aims to compare the impact of human capital (HC) 
and friction cost (FC) methods on productivity costs and incremental cost-effective-
ness ratios (ICERs) of replacing IIV3 with either high dose (HD) or quadrivalent (IIV4) 
among adults aged 65 and over in Ontario. METHODS: Population-level influenza 
outcomes from either Ontario or Canada with provincial wage data set were used 
to calculate the productivity loss due to physician visits, ED visits, hospitalizations 
and premature deaths. Vaccines efficacies were extracted from clinical studies and 
published literatures. HC and FC utilized discounted life expectancy and 90-day 
friction period, respectively. Alternative friction periods and elasticity factors were 
analyzed. RESULTS: With IIV3 under the current Universal Influenza Immunization 
Program (UIIP), the productivity costs due to influenza-related premature mortality 
is C$11.92/person and C$0.86/person with HC and FC approach, respectively. Those 
per person for HD in place of IIV3 would be C$9.13 (HC) and C$0.65 (FC); for IIV4, 
